Related Experiment Video

Updated: Aug 17, 2026

Scanning Electron Microscopy of Macerated Tissue to Visualize the Extracellular Matrix
10:21

Scanning Electron Microscopy of Macerated Tissue to Visualize the Extracellular Matrix

Published on: June 14, 2016

Prognosis of hypertrophic cardiomyopathy

F J Ten Cate1

  • 1Thoraxcentre, University Hospital, The Netherlands.

Journal of Insurance Medicine (New York, N.Y.)
|December 9, 1995
PubMed

Insights

Hypertrophic Cardiomyopathy (HCM) has a better prognosis than previously believed, with a 1% annual cardiac mortality rate. This finding impacts risk assessment for patients with this heart condition.

Area of Science:

  • Cardiology
  • Cardiovascular Medicine
  • Clinical Research

Background:

  • The long-term prognosis of Hypertrophic Cardiomyopathy (HCM), a condition historically associated with high sudden death risk, remains unclear.
  • Previous assumptions about HCM's prognosis may be overestimated, necessitating a re-evaluation of patient risk.
  • Understanding the true prognosis is crucial for effective patient management and counseling.

Purpose of the Study:

  • To prospectively evaluate the long-term cardiac mortality in a large cohort of patients diagnosed with Hypertrophic Cardiomyopathy.
  • To assess cardiac mortality in the overall HCM population and identify specific subgroups potentially at higher risk.
  • To provide a more accurate prognosis for HCM based on extended clinical follow-up.

Main Methods:

  • A prospective study of 113 patients with Hypertrophic Cardiomyopathy (HCM) was conducted.
  • Diagnosis of HCM was confirmed by echocardiography, identifying left ventricular hypertrophy without other causes.
  • Cardiac mortality was tracked over a minimum of nineteen years, with analysis of risk factors.

Main Results:

  • The study recorded 11 cardiac deaths and 2 non-cardiac deaths over the follow-up period.
  • The annual cardiac mortality rate for HCM was determined to be 1% (95% CI: 0.2-1.8%).
  • No significant difference in cardiac death risk was observed in subgroups typically considered high-risk, including young patients, those with a family history, syncope, or ventricular tachycardia.

Conclusions:

  • Hypertrophic Cardiomyopathy (HCM) demonstrates a relatively benign prognosis, with an annual cardiac mortality rate significantly lower than previously estimated.
  • These findings suggest a need to revise current risk stratification strategies for individual HCM patients.
  • Echocardiography is essential for diagnosing HCM, quantifying hypertrophy, and differentiating it from conditions like Athlete's Heart.
Abstract

More Related Videos

An Approach to Study Shape-Dependent Transcriptomics at a Single Cell Level06:02

An Approach to Study Shape-Dependent Transcriptomics at a Single Cell Level

Published on: November 2, 2020

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model03:45

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model

Published on: August 8, 2022

Related Concept Videos

Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Cardiomyopathy I: Introduction and Classification01:25

Cardiomyopathy I: Introduction and Classification

Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...